Chordomas are very rare bone malignant tumours that have had a shortage of effective treatments for a long time. New treatments are now available for both the local and the metastatic phase of the disease, but the degree of uncertainty in selecting the most appropriate treatment remains high and their adoption remains inconsistent across the world, resulting in suboptimum outcomes for many patients. In December, 2013, the European Society for Medical Oncology (ESMO) convened a consensus meeting to update its clinical practice guidelines on sarcomas. ESMO also hosted a parallel consensus meeting on chordoma that included more than 40 chordoma experts from several disciplines and from both sides of the Atlantic, with the contribution and sponsorship of the Chordoma Foundation, a global patient advocacy group. The consensus reached at that meeting is shown in this position paper.
Stacchiotti S., A. C., Blay, J., Bollè, S., Boriani, S., Capanna, R., Casali, P., Debus, J., Delaney, T., Doglietto, F., Flanagan, A., Fossati, P., Froelich, S., Gelderblom, H., Grimer, R., Gronchi, A., Haas, R., Hohenberger, P., Hornicek, F., Jeys, L., Kasper, B., Keulen, H., Krengli, M., Leithner, A., Martin-Broto, J., Morosi, C., Nicolai, P., Norum, O., Peul, W., Pilotti, S., Radaelli, S., Rutkowski, P., Scheipl, S., Tamborini, E., Torri, V., Uhl, M., Vanel, D., Vleggeert-Lankamp, C., Weber, D., Sommer, J., Building a global consensus approach to chordoma: a position paper from the medical and patient community, <<THE LANCET ONCOLOGY>>, 2015; 16 (2): 71-83. [doi:10.1016/S1470-2045(14)71190-8] [https://hdl.handle.net/10807/268824]
Building a global consensus approach to chordoma: a position paper from the medical and patient community
Doglietto, Francesco;
2015
Abstract
Chordomas are very rare bone malignant tumours that have had a shortage of effective treatments for a long time. New treatments are now available for both the local and the metastatic phase of the disease, but the degree of uncertainty in selecting the most appropriate treatment remains high and their adoption remains inconsistent across the world, resulting in suboptimum outcomes for many patients. In December, 2013, the European Society for Medical Oncology (ESMO) convened a consensus meeting to update its clinical practice guidelines on sarcomas. ESMO also hosted a parallel consensus meeting on chordoma that included more than 40 chordoma experts from several disciplines and from both sides of the Atlantic, with the contribution and sponsorship of the Chordoma Foundation, a global patient advocacy group. The consensus reached at that meeting is shown in this position paper.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
